Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Recruiting
Observational Study
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Myelodysplastic Syndromes
Hematological Malignancies
B-cell Malignancy, Low-grade
Myelodysplastic Syndrome With Low-grade Lesions
IgG Monoclonal Gammopathy of Uncertain Significance
Smoldering Multiple Myeloma
Waldenstrom Macroglobulinemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 10,000 (estimated)
- Sponsor
- Dana-Farber Cancer Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these discoveries have led to the development of new drugs that target those alterations. More remain to be…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with Known or Suspected Precursor Hematological Cancer
* Including the following subgroups of diseases:
* Early MDS, including pathologically-confirmed MDS (IPSS Low/Int-1; IPSS-R Very Low/Low) and idiopathic cytopenias of undetermined significance (ICUS);
* Asym…
Contacts